Actavis eyes $100 million after OxyContin settlement
Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP.
Orchid invests in new European pharma
Indian pharmaceutical company Orchid Chemicals and Pharmaceuticals has entered into a partnership with new European biopharmaceutical company Allecra Therapeutics.
FTC critical of pay-for-delay in annual report
The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.
Shionogi sues Hospira to block Doribax generic
Japanese pharma Shionogi has brought a lawsuit against Hospira Inc to keep it from marketing a generic version of Shionogi’s Doribax, alleging it infringes one of the company’s patents.
OFT accuses GSK of market abuse over pay-for-delay deals
The UK Office of Fair Trading has accused GlaxoSmithKline of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.
Novartis sues three over generic Zometa
Swiss pharmaceutical firm Novartis has filed a lawsuit against Accord Healthcare, Fresenius Kabi and Hikma Farmaceutica for applying to market generic versions of its cancer drug Zometa.
Myriad: the oral arguments
The US Supreme Court has heard oral arguments on whether genetic material is patent eligible subject matter. Jennifer Camacho, shareholder at Greenberg Traurig, reports on Monday's proceedings.
Supreme Court to hear oral arguments in Myriad case
Myriad Genetics will deliver an oral argument at the US Supreme Court today defending its patents covering isolated human gene sequences linked to breast and ovarian cancer.
USPTO names Patents for Humanity winners
The US Patent and Trademark Office has announced the winners of its Patents for Humanity competition, which recognises patent owners and licensees addressing global health and development challenges.
US appeals court reverses £482 million Johnson & Johnson verdict
The US Court of Appeals for the Federal Circuit has reversed a $482 million jury decision against Johnson & Johnson subsidiary Cordis, ruling that its Cypher stent did not infringe a patent held by radiologist Bruce Saffran.
